Trading Update

Lifeline Scientific, Inc.

("Lifeline" or the "Company")

Trading Update

Lifeline Scientific (AIM: LSIC), the transplantation technology company, provides the following trading update for the year ended 31 December 2014.

Lifeline had another successful second half of the year indicated by growing market adoption and continued positive clinical evidence reported in support of the Company's lead products,. The Company saw strong performance within North America as well as further significant orders from China for its flagship LifePort® Kidney Transporter and related portfolio of products.

The Company expects to report full year revenues ahead of market expectations with total revenues for the period up 6% to US$35.2m (2013: US$33.2m). A key measure of the Company's growth, the sale of proprietary single-use consumables associated with the LifePort Kidney Transporter, improved by 12% compared to last year (2013: US$18.4m).

While substantial investments in international market expansion and product line extensions continued during 2014, the Company saw operating profit, adjusted for non-recurring items, improve significantly from the US$0.9m recorded last year. As a result, 2014 Operating Profit, adjusted for non-recurring items, will also be ahead of market expectations and therefore above US$2.2m.

The cash position of the Company remains strong, with cash balances as at 31 December 2014 in line with levels recorded in the previous year (31 December 2013: US$3.0m).

David Kravitz, CEO of Lifeline Scientific, commented:

"We are very encouraged by the continued growth of LifePort adoption and use, especially within our established North American market, and that sales have continued to grow in China, where our products are being sold under clinical research protocols while awaiting full Chinese regulatory clearances. The very recent regulatory approval in China for our market leading preservation solutions is a positive sign that regulatory approval for our LifePort Kidney Transporter and it's suite of related single-use consumables could soon follow. We are also pleased to see growing clinical evidence that LifePort is improving patient outcomes and lowering overall costs in renal transplantation. Whilst progress in Brazil has been slower than expected, clinician demand and clinical outcome success in key Brazilian transplant centers is strong and we expect to see a significant pick-up in 2015. Despite these delays we are grateful to be able to report overall Company results ahead of expectations. I look forward to providing a more detailed review of the business in our full year results statement."

The Company will announce results for the year ended 31 December 2014 on Monday 27 April 2015.

For further information:

About Lifeline Scientific Inc.

Lifeline Scientific, Inc. is a Chicago-based global medical technology company with regional offices in Brussels and Sao Paulo. The Company's focus is the development of innovative products that improve transplant outcomes and lower the overall costs of transplantation. Its lead product, LifePort Kidney Transporter, is the global market-leading medical device for hypothermic machine preservation of donor kidneys. LifePorts and novel solutions designed for preservation of other organs are in development, with LifePort Liver Transporter next in line for commercial launch. For more information please visit www.lifeline-scientific.com

About LifePort Kidney Transporter

Created with the challenges of organ recovery and transport in mind, LifePort Kidney Transporter is a proprietary medical device designed to help improve kidney preservation, evaluation and transport prior to transplantation. It has been widely studied in clinical trials throughout the world and is the standard of care for machine preservation of kidneys. Employed by surgeons in over 185 leading transplant programmes in 27 countries, LifePorts have successfully preserved over 47,000 kidneys indicated for clinical transplant. For more information please visit www.organ-recovery.com

About LifePort Liver Transporter

LifePort Liver Transporter is modeled upon the clinically proven technology platform of LifePort Kidney Transporter and the Company's early HMP prototype successfully used in clinical transplant studies by surgeons at New York-Presbyterian Hospital/Columbia University Medical Center. LifePort Liver Transporter and the Company's proprietary machine preservation solution, Vasosol®, are in the process of US and European regulatory registrations. The system is designed to help improve outcomes in liver transplantation by enabling the clinical use of hypothermic machine perfusion, and has been developed in consultation with clinical and research teams specializing in liver transplantation at Columbia University Medical Center and the University of Chicago. The system employs a rugged, streamlined ergonomic design for ease of use and transportability from donor bedside to recipient operating room. For more information please visit: http://www.organ-recovery.com/pipeline.php